盘点:眼科手术并发症及治疗措施

2018-10-21 MedSci MedSci原创

Undersea Hyperb Med:暴露在高压氧治疗后眼部变量立即产生短期效应 挪威卑尔根大学医学院临床医学系的Evanger K近日在Undersea Hyperb Med发表了一项重要的工作,他们对患者进行高压氧(HBO2)治疗的6周期间,每周两次反复暴露于高压氧(HBO2)中,并测量治疗之前和之后的眼屈光度、角膜厚度、角膜半径、角膜屈光度、角膜散光和眼压等参数。 他们总共研究

Undersea Hyperb Med:暴露在高压氧治疗后眼部变量立即产生短期效应

挪威卑尔根大学医学院临床医学系的Evanger K近日在Undersea Hyperb Med发表了一项重要的工作,他们对患者进行高压氧(HBO2)治疗的6周期间,每周两次反复暴露于高压氧(HBO2)中,并测量治疗之前和之后的眼屈光度、角膜厚度、角膜半径、角膜屈光度、角膜散光和眼压等参数。

他们总共研究了23名患者,在单独的房间内,每天让患者接受HBO2治疗90分钟,为期六周,每周五天。将Topcon TRK-1P仪器安装在高压舱旁边以记录眼部的测量值。

在治疗六周的过程中,右眼的总近视移位为-0.95±0.54D(P <0.001),左眼的为-0.95±0.53D(P <0.001)。在HBO2单次暴露后,立即出现近视移位逆转、角膜变薄和眼压降低的临床症状,但在患者参加下一次测量之前表型又恢复到治疗前状态。

因此,他们认为,在HBO2治疗期间,眼部变量受到累积效应和短期影响的双重作用。短期效应表明,暴露在HBO2后进行眼部测量的时间点可能会影响检测结果。

原文出处:Evanger, K., G. Vaagbo, and O.H. Haugen, Short-term effects on ocular variables immediately after hyperbaric oxygen exposures. Undersea Hyperb Med, 2018. 45(4): p. 395-402.

J AAPOS:在斜视手术中使用GenTeal凝胶后出现慢性炎性肉芽肿

明尼苏达州明尼阿波利斯大学眼科学与视觉神经科学系的Areaux RG Jr等近日在J AAPOS上发表了文章,他们报告称在斜视手术中使用GenTeal凝胶后,出现慢性炎性肉芽肿。

在手术治疗斜视,使用GenTeal凝胶润滑角膜时,2名患者发生结膜下肉芽肿大。作者报告了结膜下结节的临床表现及组织病理学特征。这些病变跟在视网膜手术中使用GenTeal凝胶和在非眼科手术中使用类似的高聚合物而产生的病变相似。

作者指出,当结膜伤口暴露在GenTeal凝胶下时,应考虑进行大量的灌洗,并且在斜视手术时,考虑使用其他替代性角膜润湿剂。

原文出处:Areaux, R.G., Jr. and A.C. Maltry, Chronic inflammatory granulomata after use of GenTeal gel during strabismus surgery. J aapos, 2018.

J AAPOS:先天性青光眼患儿的青光眼引流装置术后出现眼球突出症

俄勒冈健康与科学大学凯西眼科研究所眼科的Alonzo B与儿童青光眼中心的Edmunds B近日在J AAPOS杂志上报告了一例病例,该病例眼睛突出,导致暴露性角膜病和运动性缺陷,在进行外科手术治疗后取得良好效果。

青光眼引流装置通常用于青光眼患儿的外科手术治疗。他们报告了一例异常的病例,该病例具有异常肿大的积液,导致眼睛突出,导致暴露性角膜病和运动性缺陷。本案例还指出,在区分青光眼患儿眼球突出病例中,B超扫描和视轴测量具有重要的作用。减少积液可以显着改善眼睛突出的情况,暴露性角膜病和运动性缺陷也可以得到缓解。

原文出处:Alonzo, B., B. Edmunds, and A.R. Loh, Proptosis masquerading as buphthalmos following glaucoma drainage device surgery in a child with congenital glaucoma. J aapos, 2018.

J Glaucoma:在植入XEN45青光眼治疗装置后发生迟发性眼内炎

西班牙马德里Tajo医院眼科的Colas-TomasT近日在J Glaucoma发表了一篇病例报告,他们发现植入XEN45装置后,发生迟发性眼内炎。

患者是一位五十四岁男性,双侧眼压升高(IOP)。患者在左眼接受了XEN45(Allergan,Inc.,Irvine,CA)植入物治疗。术后一个月,患者需要丝裂霉素C进行辅助治疗。六个月后,IOP可以通过治疗得到很好的控制。

然而,在手术后8个月,患者送入急诊室,并被诊断为左眼眼内炎。并没有创伤。由于结膜炎症明显,糜烂症状广泛存在,在支架的结膜周围观察到巩膜坏死斑。玻璃体培养物发现,对口腔链球菌呈阳性。血培养呈阴性,体检也排除了其他任何的内源性原因。鉴于临床进展不良、持续感染和失去视觉的预期,对该患者进行了眼球摘除手术。

因此,在所呈现的情况下,他们认为结膜穿孔是患者眼内炎的最可能原因。从本案例与之前的病例看出,手术后定期随访患者是十分重要的。虽然侵入性较小且看似更安全,但用于青光眼手术的新一代植入物并非完全没有并发症。

原文出处:Colas-Tomas, T. and S. Perez-Trigo, Delayed-onset Endophthalmitis Following Implantation of a XEN45(R) Glaucoma Device: A Case Report. J Glaucoma, 2018.

PLoS One:白内障手术后糖尿病视网膜病变的发生研究

台湾台北医科大学双河医院眼科的Jeng CJ近日在PLoS One上发表了一篇重要的文章,探讨了白内障手术是否会导致原先没有糖尿病视网膜病变(DR)的糖尿病患者出现糖尿病视网膜病变(DR)。

他们从健康保险数据库中选择诊断为II型糖尿病但无DR的患者。在2000年1月1日至2010年12月31日期间接受白内障手术的患者被纳入病例组,对照组按年龄、性别和特定年份与案例组相匹配。非增殖性糖尿病视网膜病变(NPDR)、增殖性糖尿病视网膜病变(PDR)和糖尿病性黄斑水肿(DME)的术后发病率是研究的主要结果,并根据年龄、性别、并发症调整他汀类药物、贝特类药物、血管紧张素转换药物等。同时,记录酶抑制剂(ACEI)、口服降糖药(OHA)和胰岛素的使用情况。

在他们的研究中,患有血脂异常和使用他汀类药物的患者更可能接受白内障手术。在没有先前DR的糖尿病患者中,接受白内障手术的患者具有较高的NDPR发生风险(校正风险比= 1.48,95%置信区间为1.15-1.91)。手术组和非手术组之间的PDR或DME的发生情况没有显着的统计学差异。在其他分层分析中,女性、年龄较大、存在并发症、5年内手术、他汀类药物、ACEI、OHA和胰岛素的使用等因素增加了NPDR的发生风险。在调整后的相关回归模型中,发现白内障手术、OHA和胰岛素的使用是NPDR发生的风险因素。存在并发症的白内障手术增加了NPDR的术后发生风险,并且白内障手术的显着影响可以持续到手术后5年。

原文出处:Jeng, C.J., et al., Development of diabetic retinopathy after cataract surgery. PLoS One, 2018. 13(8): p. e0202347.

Retina:视网膜剥离手术引起内界膜剥离后与Alport综合征相似

名古屋大学医学研究科眼科的Fukukita H近日在Retina上发表了一篇有趣的文章。视网膜的最内层基底膜,也就是内界膜(ILM),有时会在玻璃体手术中被剥离。他们探究了ILM丢失后对视网膜的影响。

他们使用光学相干断层扫描技术,对26例玻璃体切除术后视网膜脱离患者进行回顾性研究,观察26只眼的视网膜变化,其中11只ILM被剥离,15只眼睛中ILM没有被剥离。此外,他们研究了三名患有Alport综合征患者的六只眼,其中ILM是遗传性受损。

结果他们观察到中央凹向视盘的凹陷显着地向内部视网膜位移,鼻区内视网膜增厚(91.9±24.3μm,210.3±31.4μm; P = 0.048),颞区视网膜内层变薄(174.3±18.3μm,142.2±23.6μm; P <0.001)。同时出现黄斑中心凹增厚,ILM未剥离为217.0±39.4μm,ILM剥离的眼睛为302.0±86.2μm,P = 0.006。Alport综合征的眼睛表现出类似的发现。

因此,他们认为,内界膜出现功能障碍后,在先天性和后天性条件下都可以引起黄斑内部视网膜的特征性变化。

原文出处:Fukukita, H., et al., INNER MACULAR CHANGES AFTER VITRECTOMY WITH INTERNAL LIMITING MEMBRANE PEELING FOR RHEGMATOGENOUS RETINAL DETACHMENT: Similarity With Alport Syndrome. Retina, 2018.

Lasers Med Sci:Wnt /β-catenin信号通路在激光光凝术后诱导多能干细胞衍生视网膜色素上皮细胞的恢复过程中具有重要作用

韩国天安市顺天乡大学附属医院眼科的Cho IH等人近日在Lasers Med Sci发表了一篇重要的研究论文。他们研究了,诱导多能干细胞分化来的视网膜色素上皮细胞(hiPSC-RPE)中的Wnt /β-catenin信号通路在激光光凝后修复过程中的作用。

他们在从hiPSC分化产生RPE细胞后,进行激光光凝。通过β-连环蛋白的表达水平来评估激光光凝后不同时间点(第1天和第5天)Wnt /β-连环蛋白信号通路的活性。对RPE细胞进行Dickkopf-1(Dkk-1)处理和不处理,分别使用乙炔基-2'-脱氧尿苷(EdU)测定法和zonula occludens-1(ZO-1)表达分析来研究激光光凝后第5天时细胞增殖和细胞与细胞连接变化。通过实时定量聚合酶链反应(qRT-PCR)研究激光光凝后第5天Wnt基因的mRNA水平。

实验发现,激光光凝后第1天和第5天hiPSC-RPE的细胞质和细胞核中存在β-连环蛋白积累,表明Wnt /β-连环蛋白信号传导通路激活。许多EdU阳性细胞也表达β-连环蛋白,但在Dkk-1处理的激光光凝后第5天EdU阳性细胞数减少,这表明Wnt /β-连环蛋白信号传导通路介导了hiPSC-RPE增殖。在激光光凝后第5天用Dkk-1处理没有降低ZO-1的表达,表明Wnt /β-连环蛋白信号传导通路介导了hiPSC-RPE的恢复过程。在在激光光凝后第5天,Wnt2b、Wnt3、Wnt5a、Wnt7a和Wnt10b的mRNA水平增加。

因此,他们认为,Wnt /β-连环蛋白信号传导通路在激光光凝后的恢复过程中起关键作用,促进hiPSC-RPE增殖。这篇文章在阐明RPE恢复的潜在机制的同时,指出通过干预Wnt /β-连环蛋白信号传导通路可能对于视网膜退行性疾病的治疗具有潜力。

原文出处:Cho, I.H., et al., The role of Wnt/beta-catenin signaling in the restoration of induced pluripotent stem cell-derived retinal pigment epithelium after laser photocoagulation. Lasers Med Sci, 2018.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1716617, encodeId=96651e16617ce, content=<a href='/topic/show?id=cb3664635bb' target=_blank style='color:#2F92EE;'>#治疗措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64635, encryptionId=cb3664635bb, topicName=治疗措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e7432279006, createdName=gjsgj, createdTime=Sat Feb 23 10:31:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994633, encodeId=61c11994633dd, content=<a href='/topic/show?id=b3e7e2866ea' target=_blank style='color:#2F92EE;'>#眼科手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72866, encryptionId=b3e7e2866ea, topicName=眼科手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 24 19:31:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956915, encodeId=da481956915bc, content=<a href='/topic/show?id=776b5441851' target=_blank style='color:#2F92EE;'>#手术并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54418, encryptionId=776b5441851, topicName=手术并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9de22500104, createdName=1249894fm73暂无昵称, createdTime=Sun Dec 09 23:31:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758038, encodeId=843b1e580384c, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Mar 23 00:31:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350102, encodeId=047f35010231, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Oct 21 23:19:36 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350092, encodeId=18183500923a, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Sun Oct 21 22:41:01 CST 2018, time=2018-10-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1716617, encodeId=96651e16617ce, content=<a href='/topic/show?id=cb3664635bb' target=_blank style='color:#2F92EE;'>#治疗措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64635, encryptionId=cb3664635bb, topicName=治疗措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e7432279006, createdName=gjsgj, createdTime=Sat Feb 23 10:31:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994633, encodeId=61c11994633dd, content=<a href='/topic/show?id=b3e7e2866ea' target=_blank style='color:#2F92EE;'>#眼科手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72866, encryptionId=b3e7e2866ea, topicName=眼科手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 24 19:31:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956915, encodeId=da481956915bc, content=<a href='/topic/show?id=776b5441851' target=_blank style='color:#2F92EE;'>#手术并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54418, encryptionId=776b5441851, topicName=手术并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9de22500104, createdName=1249894fm73暂无昵称, createdTime=Sun Dec 09 23:31:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758038, encodeId=843b1e580384c, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Mar 23 00:31:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350102, encodeId=047f35010231, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Oct 21 23:19:36 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350092, encodeId=18183500923a, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Sun Oct 21 22:41:01 CST 2018, time=2018-10-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1716617, encodeId=96651e16617ce, content=<a href='/topic/show?id=cb3664635bb' target=_blank style='color:#2F92EE;'>#治疗措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64635, encryptionId=cb3664635bb, topicName=治疗措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e7432279006, createdName=gjsgj, createdTime=Sat Feb 23 10:31:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994633, encodeId=61c11994633dd, content=<a href='/topic/show?id=b3e7e2866ea' target=_blank style='color:#2F92EE;'>#眼科手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72866, encryptionId=b3e7e2866ea, topicName=眼科手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 24 19:31:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956915, encodeId=da481956915bc, content=<a href='/topic/show?id=776b5441851' target=_blank style='color:#2F92EE;'>#手术并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54418, encryptionId=776b5441851, topicName=手术并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9de22500104, createdName=1249894fm73暂无昵称, createdTime=Sun Dec 09 23:31:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758038, encodeId=843b1e580384c, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Mar 23 00:31:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350102, encodeId=047f35010231, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Oct 21 23:19:36 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350092, encodeId=18183500923a, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Sun Oct 21 22:41:01 CST 2018, time=2018-10-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1716617, encodeId=96651e16617ce, content=<a href='/topic/show?id=cb3664635bb' target=_blank style='color:#2F92EE;'>#治疗措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64635, encryptionId=cb3664635bb, topicName=治疗措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e7432279006, createdName=gjsgj, createdTime=Sat Feb 23 10:31:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994633, encodeId=61c11994633dd, content=<a href='/topic/show?id=b3e7e2866ea' target=_blank style='color:#2F92EE;'>#眼科手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72866, encryptionId=b3e7e2866ea, topicName=眼科手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 24 19:31:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956915, encodeId=da481956915bc, content=<a href='/topic/show?id=776b5441851' target=_blank style='color:#2F92EE;'>#手术并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54418, encryptionId=776b5441851, topicName=手术并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9de22500104, createdName=1249894fm73暂无昵称, createdTime=Sun Dec 09 23:31:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758038, encodeId=843b1e580384c, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Mar 23 00:31:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350102, encodeId=047f35010231, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Oct 21 23:19:36 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350092, encodeId=18183500923a, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Sun Oct 21 22:41:01 CST 2018, time=2018-10-21, status=1, ipAttribution=)]
    2019-03-23 丁鹏鹏
  5. [GetPortalCommentsPageByObjectIdResponse(id=1716617, encodeId=96651e16617ce, content=<a href='/topic/show?id=cb3664635bb' target=_blank style='color:#2F92EE;'>#治疗措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64635, encryptionId=cb3664635bb, topicName=治疗措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e7432279006, createdName=gjsgj, createdTime=Sat Feb 23 10:31:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994633, encodeId=61c11994633dd, content=<a href='/topic/show?id=b3e7e2866ea' target=_blank style='color:#2F92EE;'>#眼科手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72866, encryptionId=b3e7e2866ea, topicName=眼科手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 24 19:31:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956915, encodeId=da481956915bc, content=<a href='/topic/show?id=776b5441851' target=_blank style='color:#2F92EE;'>#手术并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54418, encryptionId=776b5441851, topicName=手术并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9de22500104, createdName=1249894fm73暂无昵称, createdTime=Sun Dec 09 23:31:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758038, encodeId=843b1e580384c, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Mar 23 00:31:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350102, encodeId=047f35010231, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Oct 21 23:19:36 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350092, encodeId=18183500923a, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Sun Oct 21 22:41:01 CST 2018, time=2018-10-21, status=1, ipAttribution=)]
    2018-10-21 医者仁心5538

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1716617, encodeId=96651e16617ce, content=<a href='/topic/show?id=cb3664635bb' target=_blank style='color:#2F92EE;'>#治疗措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64635, encryptionId=cb3664635bb, topicName=治疗措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e7432279006, createdName=gjsgj, createdTime=Sat Feb 23 10:31:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994633, encodeId=61c11994633dd, content=<a href='/topic/show?id=b3e7e2866ea' target=_blank style='color:#2F92EE;'>#眼科手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72866, encryptionId=b3e7e2866ea, topicName=眼科手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 24 19:31:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956915, encodeId=da481956915bc, content=<a href='/topic/show?id=776b5441851' target=_blank style='color:#2F92EE;'>#手术并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54418, encryptionId=776b5441851, topicName=手术并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9de22500104, createdName=1249894fm73暂无昵称, createdTime=Sun Dec 09 23:31:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758038, encodeId=843b1e580384c, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Mar 23 00:31:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350102, encodeId=047f35010231, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Oct 21 23:19:36 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350092, encodeId=18183500923a, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Sun Oct 21 22:41:01 CST 2018, time=2018-10-21, status=1, ipAttribution=)]
    2018-10-21 王秀

    学习了,涨知识了!

    0

相关资讯

Undersea Hyperb Med:暴露在高压氧治疗后眼部变量立即产生短期效应

挪威卑尔根大学医学院临床医学系的Evanger K近日在Undersea Hyperb Med发表了一项重要的工作,他们对患者进行高压氧(HBO2)治疗的6周期间,每周两次反复暴露于高压氧(HBO2)中,并测量治疗之前和之后的眼屈光度、角膜厚度、角膜半径、角膜屈光度、角膜散光和眼压等参数。

盘点:眼科系统解决方案

Am J Ophthalmol:早产儿视网膜疾病的系统性解决方案 美国斯坦福大学医学院眼科学院Byers眼科研究所视网膜科主任Moshfeghi DM近日在Am J Ophthalmol发表了一篇文章,他们使用激光和血管内皮生长因子抑制剂治疗方法,建立了远程医学筛查和治疗早产儿视网膜病的框架。 他们采用查阅文献的方法,对相关文献和作者的经验结果进行分析。远程医疗可以在全国范围内使用,可

Surv Ophthalmol:眼科人工智能的现状

布法罗大学雅各布医学院的Kappor R和美国纽约哈克尼斯眼科研究所的Walters SP近日在 Surv Ophthalmol杂志上发表了一篇重要综述文章,作者概述了人工智能的基本原理,以及这些原理对于理解人工智能及其在医疗保健中的应用。

盘点:眼科亮点综述

Surv Ophthalmol:系统评价营养补充对青光眼的辅助治疗疗效 爱尔兰眼科研究中心的Loskutova E等人近日在Surv Ophthalmol杂志上发表了一篇文章,他们系统的讨论了营养补充剂对青光眼的辅助治疗疗效。 目前针对青光眼的治疗方案仅能达到阻止疾病发展的目的,不能恢复丧失的视觉功能。眼压(IOP)是青光眼的主要危险因素,降低IOP仍然是青光眼治疗的主要方案。即使成功

盘点:眼科组学研究

PeerJ:20例高度近视患者的外显子组测序研究 四川大学华西医院眼科的Wan L等近日在PeerJ杂志上发表了一项重要的工作。高度近视是全世界常见的眼部疾病。为了扩展人们对高度近视遗传基础的理解,他们进行了一项完整的外显子组测序(WES)研究,以确定潜在的突变基因。 他们对高度近视的总共20个个体进行了外显子组测序。结合表型和突变体的功能障碍,采用新型过滤策略,进行多步生物信息学分析

盘点:眼科临床基础研究

PLoS One:糖尿病性黄斑水肿患者房水中的细胞因子水平对抗VEGF治疗 韩国天主教大学医学院圣文森特医院眼科学与视觉科学系的Kwon JW等近日在PLoS One上发表了一篇文章,确定水溶性细胞因子与糖尿病性黄斑水肿(DME)中玻璃体内注射贝伐单抗(IVB)反应的相关性。 研究群体是64名DME患者,其中有13名白内障患者。他们比较了患者房水中IL(白介素)-1β、IL-2、IL-